Marissa Ceresnie, DO

Speaker Details
  • Abstract Title

    Investigating Disparities in Recording Race and Ethnicity in Vitiligo Clinical Trial Screening Assessments

  • Abstract Take Home Message

    Vitiligo clinical trial screening assessment forms may not be accurately or precisely classifying the race and ethnicity of subjects. Retrospective review of demographic sections on screening assessment forms included in industry-initiated vitiligo clinical trials over the past 10 years at our institution list limited race and ethnicity choices that are often ambiguous, potentially leading to inaccurate and imprecise subject reporting. This suggests certain race and ethnicity groups, such as Middle Eastern and South Asian populations, may be underrepresented in industry-initiated vitiligo clinical trials. This finding may affect the generalizability and interpretation of vitiligo clinical trial results for all races and ethnic groups.

  • Additional Authors

    Angela Parks-Miller, CCRP, CWCA, Iltefat H. Hamzavi, MD

  • Disclosures

    MSC serves as a sub-investigator for Avita Recell, Immune Tolerance Network, and the Incyte Corporation with funding received by the institution.

    APM has no relevant disclosures.

    IHH has served as an advisory board member for AbbVie; a consultant for Incyte Corporation, Pfizer, and UCB; a principal investigator for AbbVie, Allergan, Avita ReCell, Bayer, Clinuvel Pharmaceuticals, Estee Lauder, Ferndale Laboratories, Galderma Laboratories LP, GE Healthcare, The Immune Tolerance Network, Incyte Corporation, Janssen, Janssen Biotech, Johnson & Johnson, Lenicura, LEO Pharma, Pfizer, and Unigen; a subinvestigator for Amgen, Bristol Myers Squibb, Foamix Pharmaceuticals, and Janssen; and co-chair of the Global Vitiligo Foundation.